MVT 5873

Drug Profile

MVT 5873

Alternative Names: 5B1-(sLeA)-therapeutic; Anti-CA19.9 antibody; anti-sialyl Lewisa antibody; HuMab MVT-5873; HuMab-5B1; HuMab-5B1 antibody; MVT-5873

Latest Information Update: 15 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MabVax Therapeutics
  • Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center; Sarah Cannon Research Institute
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer; Colorectal cancer; Pancreatic cancer
  • Preclinical Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 12 Feb 2018 Interim efficacy, adverse events, pharmacodynamics data from phase I trial in Pancreatic cancer released by MabVax Therapeutics
  • 31 Oct 2017 Additional efficacy data from a phase I trial in Pancreatic cancer released by MabVax Therapeutics
  • 31 Oct 2017 Pharmacodynamics data from a preclinical study in cancer released by MabVax Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top